Search results for "Blood glucose"

showing 10 items of 437 documents

Advances in pharmacological treatment of type 1 diabetes during pregnancy.

2019

Introduction: In women with type 1 diabetes mellitus (T1DM), pregnancy is associated with a potential risk of maternal, foetal and neonatal outcomes. Stringent metabolic control is required to improve these outcomes. Areas covered: In this review, the authors summarise the current evidence from studies on the pharmacological therapy and on monitoring of T1DM during pregnancy. The authors also discuss the use of new technologies to improve therapeutic management and patient compliance. Expert opinion: Pre-conception counselling is essential in T1DM to minimise pregnancy risks. Pregnancy in T1DM is always considered a high-risk pregnancy. During pregnancy, the target haemoglobin A1C (HbA1c) i…

Blood Glucoseendocrine system diseasesPregnancy in DiabeticsDiabetic complicationBioinformaticsPharmacological treatmenttype 1 diabetes mellitu03 medical and health sciences0302 clinical medicinePregnancymedicineHumansHypoglycemic AgentsInsulinPharmacology (medical)PharmacologyType 1 diabetesPregnancyPotential riskbusiness.industryCesarean Sectionnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemiaglycaemic controlDiabetes Mellitus Type 1Neonatal outcomes030220 oncology & carcinogenesisMetabolic control analysisFemalebusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

Intraportal transplantation of allogenic pancreatic islets encapsulated in barium alginate beads in diabetic rats.

2003

The survival of microencapsulated islets transplanted into the unmodified peritoneal cavity is limited, even if capsular overgrowth is restricted to a minimum, due to an insufficient oxygen supply to the islets. Therefore, research efforts should focus on finding or creating a transplantation site, which permits a closer contact between the encapsulated islets and the blood. For this reason, the liver could be an interesting candidate. The aim of the present study was to test the hypothesis that the intraportal transplantation of allogenic islets encapsulated in small-sized barium alginate beads is safe and succeeds to induce normoglycemia in diabetic rats. The intraportal transplantation o…

Blood Glucoseendocrine systemmedicine.medical_specialtyAlginatesDrug CompoundingBiomedical EngineeringIslets of Langerhans TransplantationMedicine (miscellaneous)Blood sugarBioengineeringDiabetes Mellitus ExperimentalBiomaterialsRats Sprague-Dawleychemistry.chemical_compoundPeritoneal cavityIslets of LangerhansGlucuronic AcidInternal medicineDiabetes mellitusmedicineAnimalsgeographyDrug Carriersgeography.geographical_feature_categoryCell DeathPancreatic isletsHexuronic AcidsGeneral MedicineGlucuronic acidIsletmedicine.diseaseSurgeryRatsTransplantationPortal Systemmedicine.anatomical_structureEndocrinologychemistryLiverRats Inbred LewDrug carrierArtificial organs
researchProduct

The effects of cold and glucagon on lipolysis, glycogenolysis and oxygen consumption in young chicks.

1973

Abstract 1. 1. To study the possible role of glucagon in avian thermoregulation the effects of cold exposure and glucagon on lipolysis, glycogenolysis and oxygen consumption were measured in young chicks. 2. 2. Cold exposure (+10°C) and glucagon injection (0·3 mg/kg, i.p. at +30°C) both caused a marked increase in the plasma FFA and a decrease in the liver glycogen content. 3. 3. It is suggested that glucagon possibly acts in the avian thermoregulation by producing at least lipolysis and glycogenolysis during cold exposure.

Blood Glucoseendocrine systemmedicine.medical_specialtyGlycogenolysisCold exposurechemistry.chemical_elementBiologyFatty Acids NonesterifiedGlucagonOxygenchemistry.chemical_compoundOxygen ConsumptionInternal medicinemedicineLipolysisAnimalsGlycogenGeneral MedicineThermoregulationGlucagonStimulation ChemicalLiver GlycogenCold TemperatureEndocrinologychemistryLiverDepression ChemicalGlucagon InjectionChickenshormones hormone substitutes and hormone antagonistsBody Temperature RegulationComparative biochemistry and physiology. A, Comparative physiology
researchProduct

Associations of resting and peak fat oxidation with sex hormone profile and blood glucose control in middle-aged women.

2022

Background and Aims Menopause may reduce fat oxidation. We investigated whether sex hormone profile explains resting fat oxidation (RFO) or peak fat oxidation (PFO) during incremental cycling in middle-aged women. Secondarily, we studied associations of RFO and PFO with glucose regulation. Method and Results We measured RFO and PFO of 42 women (age 52–58 years) with indirect calorimetry. Seven participants were pre- or perimenopausal, 26 were postmenopausal, and nine were postmenopausal hormone therapy users. Serum estradiol (E2), follicle-stimulating hormone, progesterone, and testosterone levels were quantified with immunoassays. Insulin sensitivity (Matsuda index) and glucose tolerance (…

Blood GlucoseestradioliNutrition and Dieteticsvaihdevuodetglucose toleranceEndocrinology Diabetes and MetabolismhapettuminenmenopauseMedicine (miscellaneous)fat oxidationGlycemic ControlMiddle Agedinsuliiniresistenssirasva-aineenvaihduntahormonaaliset tekijätGlucoseglukoosi-intoleranssiestradiolBody Compositioninsulin sensitivityHumansFemaleInsulin ResistanceCardiology and Cardiovascular MedicineGonadal Steroid HormonesNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month re…

2018

OBJECTIVE Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement of anthropometric and metabolic parameters. The aim of the study was to evaluate the effects of DR-HC on insulin secretion and sensitivity and cardiometabolic risk, indirectly expressed by the visceral adiposity index (VAI). DESIGN AND PATIENTS Retrospective analysis of 49 patients, 13 with primary and 36 with secondary adrenal insufficiency (AI), respectively, on conventional glucocorticoid treatment at baseline and switched to DR-HC for 36 months. Overall, 24 patients had AI-pre-diabetes (impaired fasting glucose, impaired glucose tolerance and the combination), and 25 had AI-…

Blood Glucoseinsulin secretionmedicine.medical_specialtyWaistHydrocortisoneEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaImpaired glucose tolerancePrediabetic State03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusGlucose IntolerancemedicineAdrenal insufficiencyHumansplenadrenPrediabetesGlucocorticoidsHydrocortisoneRetrospective Studiesbusiness.industryAdrenal insufficiency; diabetes; dual-release hydrocortisone; insulin secretion; plenadren; Endocrinology Diabetes and MetabolismFastingImpaired fasting glucosemedicine.diseaseEndocrinologydiabetedual-release hydrocortisoneInsulin ResistanceWaist CircumferencebusinessGlucocorticoidmedicine.drugAdrenal InsufficiencyClinical endocrinology
researchProduct

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

2018

Abstract Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be ‘silent’ or ‘asymptomatic’, but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anti…

Blood Glucoselcsh:Diseases of the circulatory (Cardiovascular) systemEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and DiabetologyDiseaseType 2 diabetes030204 cardiovascular system & hematologySilent0302 clinical medicineRisk FactorsMass ScreeningAsymptomatic ; Atypical ; Cardiovascular disease ; Screening ; Silent ; Type 2 diabetes ; Unrecognised.Type 2 diabetesCardiovascular diseasePrognosisAsymptomatic3. Good health2712 Endocrinology Diabetes and MetabolismCardiovascular DiseasesScreeningmedicine.symptomCardiology and Cardiovascular Medicinemedicine.medical_specialtyPrognostic factor030209 endocrinology & metabolism610 Medicine & healthRisk AssessmentAsymptomatic2705 Cardiology and Cardiovascular Medicine03 medical and health sciencesPredictive Value of TestsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsIntensive care medicineUnrecognisedbusiness.industrymedicine.diseaseEarly DiagnosisDiabetes Mellitus Type 2lcsh:RC666-7012724 Internal MedicineHeart failureAsymptomatic DiseasesCommentarybusinessAtypicalBiomarkers
researchProduct

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

2015

Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T an…

Blood Glucoselcsh:MedicineBlood Pressureurologic and male genital diseasesTriglycerideBody Mass IndexAntineoplastic Agentchemistry.chemical_compoundRetrospective StudieRenal cell carcinomalcsh:ScienceMultidisciplinaryKidney NeoplasmKidney NeoplasmsSurvival RateEverolimuCholesterolDisease ProgressionHumanmedicine.drugResearch ArticleAdultmedicine.medical_specialtyAdolescentUrologyBlood sugarAntineoplastic AgentsYoung AdultInternal medicinemedicineCarcinomaHumansEverolimusCarcinoma Renal CellTriglyceridesNeoplasm StagingRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)EverolimusCholesterolbusiness.industrylcsh:RCarcinomaRenal CellAdolescent; Adult; Antineoplastic Agents; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Carcinoma Renal Cell; Cholesterol; Disease Progression; Everolimus; Humans; Kidney Neoplasms; Lipid Metabolism; Neoplasm Staging; Retrospective Studies; Survival Rate; Triglycerides; Young Adult; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Lipid metabolismBiomarkermedicine.diseaseLipid Metabolismrenal; carcinomaBlood pressureEndocrinologyAgricultural and Biological Sciences (all)chemistryPharmacodynamicslcsh:QbusinessBiomarkersPloS one
researchProduct

The effects of 12-week progressive strength training on strength, functional capacity, metabolic biomarkers, and serum hormone concentrations in heal…

2018

Previous findings suggest that performing strength training (ST) in the evening may provide greater benefit for young individuals. However, this may not be optimal for the older population. The purpose of this study was to compare the effects of a 12-week ST program performed in the morning vs. evening on strength, functional capacity, metabolic biomarker and basal hormone concentrations in older women. Thirty-one healthy older women (66 ± 4 years, 162 ± 4 cm, 75 ± 13 kg) completed the study. Participants trained in the morning (M) (07:30, n = 10), in the evening (E) (18:00, n = 10), or acted as a non-training control group (C) (n = 11). Both intervention groups performed whole-body strengt…

Blood Glucosemaximum strengthmedicine.medical_specialtyEveningWeight LiftingPhysiologyStrength trainingRestBlood lipidsMuscle hypertrophysenior fitness testsresistance03 medical and health sciencesFollicle-stimulating hormone0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumanstime of the dayTestosteroneMuscle StrengthLeg pressMuscle Skeletalta315vuorokaudenajatMorningAgedblood lipidsbusiness.industryagingResistance Training030229 sport sciencesCircadian RhythmharjoitusvasteEndocrinologyikääntyminenFemalevoimaharjoitteluLuteinizing hormonebusiness030217 neurology & neurosurgeryBiomarkersikääntyneetChronobiology International
researchProduct

Hydroxychloroquine, COVID ‐19 and diabetes. Why it is a different story

2020

Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.

Blood Glucosemedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Endocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINE030209 endocrinology & metabolismGlycemic Control030204 cardiovascular system & hematologySeverity of Illness IndexDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyCommentariesInternal medicineDiabetes mellitusSeverity of illnessDiabetes MellitusInternal MedicinemedicineHyperglycaemiaHumansHypoglycemic AgentsBlood Glucose COVID-19 Diabetes Complications Diabetes Mellitus Glycemic Control Humans Hydroxychloroquine Hypoglycemic Agents SARS-CoV-2 Severity of Illness Index Signal TransductionSARS-CoV-2business.industryDiabetesCOVID-19Hydroxychloroquinemedicine.diseaseCOVID-19 Drug TreatmentACE2 Cardiovascular disease COVID‐19CommentarybusinessHydroxychloroquineSignal Transductionmedicine.drugDiabetes/Metabolism Research and Reviews
researchProduct

Glucose and Erythrocyte ATP: Distinctive Effects of Dipyridamole and of Ticlopidine

1987

This experiment suggests the following points: 1. Erythrocytes in control patients and in atherosclerosis patients seem to have a variable grade of affinity for adenosine and for plasma glucose. This variable grade seems to fix the level of the adenosine triphosphate (ATP) reserves and induces the erythrocytes' deformability. 2. The drop in the level of ATP reserves that induces the poor deformability of the erythrocytes in atherosclerosis patients would appear to be caused by two consecutive shortages: first a shortage that seems to be related to a deficiency of erythrocyte adenosine as the ATP shortage disappears with dipyridamole treatment and then a shortage induced by the lack of eryt…

Blood Glucosemedicine.medical_specialtyAdenosineErythrocytesTiclopidineArteriosclerosismedicine.medical_treatmentEconomic shortage030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundAdenosine Triphosphate0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineTiclopidineChemotherapyPlasma glucosebusiness.industryDipyridamoleAdenosineDipyridamoleRed blood cellEndocrinologymedicine.anatomical_structurechemistryDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessAdenosine triphosphatemedicine.drugAngiology
researchProduct